#ORPH Open Orphan – £10.4m contract with existing Big Pharma client

hVIVO to develop new influenza challenge strain to test oral antiviral candidate   Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing […]